- Home
- NVAX vs RCKT Comparison
NVAX vs RCKT Comparison
Compare NVAX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- RCKT
- Stock Information
- Founded
- NVAX 1987
- RCKT 1999
- Country
- NVAX United States
- RCKT United States
- Employees
- NVAX N/A
- RCKT N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- NVAX Health Care
- RCKT Health Care
- Exchange
- NVAX Nasdaq
- RCKT Nasdaq
- Market Cap
- NVAX 2.0B
- RCKT 1.9B
- IPO Year
- NVAX 1995
- RCKT N/A
- Fundamental
- Price
- NVAX $9.76
- RCKT $17.13
- Analyst Decision
- NVAX Buy
- RCKT Strong Buy
- Analyst Count
- NVAX 6
- RCKT 9
- Target Price
- NVAX $17.83
- RCKT $53.22
- AVG Volume (30 Days)
- NVAX 7.2M
- RCKT 731.3K
- Earning Date
- NVAX 11-07-2024
- RCKT 11-04-2024
- Dividend Yield
- NVAX N/A
- RCKT N/A
- EPS Growth
- NVAX N/A
- RCKT N/A
- EPS
- NVAX N/A
- RCKT N/A
- Revenue
- NVAX $987,667,000.00
- RCKT N/A
- Revenue This Year
- NVAX N/A
- RCKT N/A
- Revenue Next Year
- NVAX N/A
- RCKT $300.20
- P/E Ratio
- NVAX N/A
- RCKT N/A
- Revenue Growth
- NVAX N/A
- RCKT N/A
- 52 Week Low
- NVAX $3.53
- RCKT $15.98
- 52 Week High
- NVAX $23.86
- RCKT $32.53
- Technical
- Relative Strength Index (RSI)
- NVAX 36.20
- RCKT 46.41
- Support Level
- NVAX $9.52
- RCKT $17.05
- Resistance Level
- NVAX $10.63
- RCKT $17.75
- Average True Range (ATR)
- NVAX 0.57
- RCKT 0.72
- MACD
- NVAX -0.12
- RCKT 0.06
- Stochastic Oscillator
- NVAX 9.97
- RCKT 40.23
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.